Form 8-K - Current report:
SEC Accession No. 0001013762-25-001260
Filing Date
2025-03-24
Accepted
2025-03-24 09:00:08
Documents
15
Period of Report
2025-03-24
Items
Item 7.01: Regulation FD Disclosure
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 CURRENT REPORT ea0235277-8k_oncon.htm   iXBRL 8-K 26091
2 PRESS RELEASE DATED MARCH 24, 2025 ea023527701ex99-1_oncon.htm EX-99.1 11194
3 ABSTRACT ea023527701ex99-2_oncon.htm EX-99.2 9744
  Complete submission text file 0001013762-25-001260.txt   230680

Data Files

Seq Description Document Type Size
4 XBRL SCHEMA FILE onco-20250324.xsd EX-101.SCH 3042
5 XBRL LABEL FILE onco-20250324_lab.xml EX-101.LAB 34240
6 XBRL PRESENTATION FILE onco-20250324_pre.xml EX-101.PRE 22377
17 EXTRACTED XBRL INSTANCE DOCUMENT ea0235277-8k_oncon_htm.xml XML 3801
Mailing Address 201 E. FIFTH STREET SUITE 1900 CINCINNATI OH 45202
Business Address 201 E. FIFTH STREET SUITE 1900 CINCINNATI OH 45202 513-620-4101
Onconetix, Inc. (Filer) CIK: 0001782107 (see all company filings)

EIN.: 000000000 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-41294 | Film No.: 25762437
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)